Related Experiment Video
Updated: Feb 17, 2026

Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis
Published on: March 19, 2019
Inhibiting mitochondrial phosphate transport as an unexploited antifungal strategy
Catherine A McLellan1,2, Benjamin M Vincent1,3, Norma V Solis4
1Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA.
Abstract:
The development of effective antifungal therapeutics remains a formidable challenge because of the close evolutionary relationship between humans and fungi. Mitochondrial function may present an exploitable vulnerability because of its differential utilization in fungi and its pivotal roles in fungal morphogenesis, virulence, and drug resistance already demonstrated by others. We now report mechanistic characterization of ML316, a thiohydantoin that kills drug-resistant Candida species at nanomolar concentrations through fungal-selective inhibition of the mitochondrial phosphate carrier Mir1. Using genetic, biochemical, and metabolomic approaches, we established ML316 as the first Mir1 inhibitor. Inhibition of Mir1 by ML316 in respiring yeast diminished mitochondrial oxygen consumption, resulting in an unusual metabolic catastrophe marked by citrate accumulation and death. In a mouse model of azole-resistant oropharyngeal candidiasis, ML316 reduced fungal burden and enhanced azole activity. Targeting Mir1 could provide a new, much-needed therapeutic strategy to address the rapidly rising burden of drug-resistant fungal infection.
Insights
Researchers identified ML316, a novel antifungal drug, that targets the fungal mitochondrial phosphate carrier Mir1. This discovery offers a promising new strategy against drug-resistant Candida infections.
Area of Science:
- Biochemistry
- Mycology
- Pharmacology
Background:
- Developing effective antifungal therapies is challenging due to the evolutionary similarity between fungi and humans.
- Fungal mitochondrial function is a potential therapeutic target, influencing morphogenesis, virulence, and drug resistance.
Purpose of the Study:
- To characterize the antifungal compound ML316 and its mechanism of action.
- To evaluate ML316 as a potential therapeutic agent against drug-resistant fungal infections.
Main Methods:
- Mechanistic characterization using genetic, biochemical, and metabolomic approaches.
- In vitro studies on drug-resistant Candida species.
- In vivo studies using a mouse model of oropharyngeal candidiasis.
Main Results:
- ML316 selectively inhibits the fungal mitochondrial phosphate carrier Mir1 at nanomolar concentrations.
- ML316 causes metabolic catastrophe in yeast by inhibiting Mir1, leading to citrate accumulation and cell death.
- ML316 reduces fungal burden and enhances azole efficacy in a mouse model of candidiasis.
Conclusions:
- ML316 is the first identified inhibitor of Mir1.
- Targeting Mir1 presents a novel therapeutic strategy for combating drug-resistant fungal infections.
- ML316 demonstrates potential as a new antifungal therapeutic.
Related Concept Videos
The Electron Transport Chain
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Drugs that Destabilize Microtubules
ATP Synthase: Mechanism
Drugs that Stabilize Microtubules
Fungal Phylum Microsporidia

